The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib
Dec 03, 2024•over 1 year ago
Contract Type
agreement
BiotechnologyHealth CareTherapeuticsBiopharma
Description
Elevar Therapeutics and Relay Therapeutics have announced an exclusive global licensing agreement for lirafugratinib (RLY-4008), a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors. The agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib.
Company Information
Company
Elevar Therapeutics and Relay Therapeutics
About
Elevar Therapeutics is a fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options. Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies.
Predictive Intelligence
Strategic
ML-powered predictions for Elevar Therapeutics and Relay Therapeutics's next move
